NO20032986L - Metoder og blandinger for påvisning av forbindelser som modulerer inflammatoriske responser - Google Patents

Metoder og blandinger for påvisning av forbindelser som modulerer inflammatoriske responser

Info

Publication number
NO20032986L
NO20032986L NO20032986A NO20032986A NO20032986L NO 20032986 L NO20032986 L NO 20032986L NO 20032986 A NO20032986 A NO 20032986A NO 20032986 A NO20032986 A NO 20032986A NO 20032986 L NO20032986 L NO 20032986L
Authority
NO
Norway
Prior art keywords
compositions
compounds
detection
methods
inflammatory responses
Prior art date
Application number
NO20032986A
Other languages
English (en)
Other versions
NO20032986D0 (no
Inventor
Sivaram Pillarisetti
Shianlen Cahoon
Uday Saxena
Original Assignee
Reddy Us Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Us Therapeutics Inc filed Critical Reddy Us Therapeutics Inc
Publication of NO20032986D0 publication Critical patent/NO20032986D0/no
Publication of NO20032986L publication Critical patent/NO20032986L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
NO20032986A 2000-12-29 2003-06-27 Metoder og blandinger for påvisning av forbindelser som modulerer inflammatoriske responser NO20032986L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25930600P 2000-12-29 2000-12-29
PCT/US2001/050818 WO2002066978A2 (en) 2000-12-29 2001-12-21 Detection of compounds that modulate inflammatory responses

Publications (2)

Publication Number Publication Date
NO20032986D0 NO20032986D0 (no) 2003-06-27
NO20032986L true NO20032986L (no) 2003-08-13

Family

ID=22984398

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032986A NO20032986L (no) 2000-12-29 2003-06-27 Metoder og blandinger for påvisning av forbindelser som modulerer inflammatoriske responser

Country Status (11)

Country Link
US (1) US7273712B2 (no)
EP (1) EP1368648A2 (no)
JP (1) JP2005501222A (no)
BR (1) BR0116606A (no)
CA (1) CA2433348A1 (no)
HU (1) HUP0600450A2 (no)
IL (1) IL156651A0 (no)
IS (1) IS6861A (no)
NO (1) NO20032986L (no)
PL (1) PL366250A1 (no)
WO (1) WO2002066978A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1334207A2 (en) * 2000-10-02 2003-08-13 Reddy US Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
HUP0600450A2 (en) * 2000-12-29 2006-09-28 Reddy Us Therapeutics Detection of compounds that modulate inflammatory responses
US20060140933A1 (en) * 2002-08-16 2006-06-29 Wyeth And Imperial College Innovations Limited Compositions and methods for treating rage-associated disorders
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
AU2005271452B2 (en) * 2004-08-03 2011-11-03 Vtv Therapeutics Llc RAGE fusion proteins and methods of use
CN101010430A (zh) * 2004-08-03 2007-08-01 转化技术制药公司 Rage融合蛋白及使用方法
US20060084184A1 (en) * 2004-10-19 2006-04-20 Renovar Incorporated Reagents for urine-based immunological assays
EP1963786B1 (en) * 2005-12-23 2013-07-24 GCoder Systems AB Positioning pattern
EP1971865B1 (en) 2006-01-10 2013-04-17 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
AU2007215503A1 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
WO2007130302A2 (en) 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
KR101595634B1 (ko) 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
WO2009063307A2 (en) * 2007-11-14 2009-05-22 Bio-Technology General (Israel) Ltd. Inflammatory activity detection method using il-6
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2012113785A1 (en) * 2011-02-21 2012-08-30 Fibrostatin S.L. Methods for treating and diagnosing disease
EP2992333A1 (en) * 2013-05-02 2016-03-09 Stichting Katholieke Universiteit Personalised medicine
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EP1334207A2 (en) * 2000-10-02 2003-08-13 Reddy US Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
HUP0600450A2 (en) * 2000-12-29 2006-09-28 Reddy Us Therapeutics Detection of compounds that modulate inflammatory responses
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds

Also Published As

Publication number Publication date
IS6861A (is) 2003-06-26
BR0116606A (pt) 2006-05-09
US20020086282A1 (en) 2002-07-04
WO2002066978A3 (en) 2003-01-23
WO2002066978A2 (en) 2002-08-29
IL156651A0 (en) 2004-01-04
PL366250A1 (en) 2005-01-24
NO20032986D0 (no) 2003-06-27
JP2005501222A (ja) 2005-01-13
CA2433348A1 (en) 2002-08-29
EP1368648A2 (en) 2003-12-10
US7273712B2 (en) 2007-09-25
HUP0600450A2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
NO20032986L (no) Metoder og blandinger for påvisning av forbindelser som modulerer inflammatoriske responser
NO20023216D0 (no) Instrumentert sementeringsplugg og system for samme
NO20030867L (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20011950L (no) Farmasöytiske blandinger som inneholder poly(ADP-ribose) glukohydrolaseinhibitorer og fremgangsmåter for anvendelse avsamme
NO20032229L (no) Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer
EP1278465A4 (en) EQUIPMENT AND METHOD FOR EXCISION BIOPSY
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
NO20020635L (no) Hemmere av proteinpolymeriserings og metodene som brukes
NO20014895D0 (no) Farmasöytisk formulering innbefattende et bisfosfonat og et additivmiddel som gir foröket adsorpsjon av bisfosfonatet
DE69719692D1 (de) Video-Inspektions- oder Bohrlochmessgerät
DE69906311D1 (de) Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
NO20033288L (no) Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer
DE60110061D1 (de) Thermoelektrischer entfeuchter
NO20005400D0 (no) Kinoloner anvendt som MRS-inhibitorer og baktericider
DE60108043D1 (de) Zerstörungsfreies Inspektionsverfahren
NO20040996L (no) Nye forbindelser og sammensetninger som catepsin-inhibitorer
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
NO20035328D0 (no) Nye forbindelser og preparater som katepsinhibitorer
NO20032856L (no) Elektronisk tunge som ozon-detektor
DE60214316D1 (de) Chirp-Messverfahren
DK0962760T3 (da) Indretning til evaluering af kvalitet af granulære objekter
DE10196444T1 (de) Prüfvorrichtung
ATE225346T1 (de) Fkbp inhibitoren
PT1263421E (pt) Avasimibe, o inibidor duplo da sintese de ester de colesterilo e de ester ceroso, para o tratamento de disturbios da glandula sebacea

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application